Halozyme Therapeutics HALO EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's EPS (diluted)?
- Halozyme Therapeutics (HALO) reported EPS (diluted) of $1.22 in Q1 2026.
- How has Halozyme Therapeutics's EPS (diluted) changed year-over-year?
- Halozyme Therapeutics's EPS (diluted) increased by 31.2% year-over-year, from $0.93 to $1.22.
- What is the long-term trend for Halozyme Therapeutics's EPS (diluted)?
- Over 3 years (2021 to 2024), Halozyme Therapeutics's EPS (diluted) has grown at a 7.6% compound annual growth rate (CAGR), from $2.75 to $3.43.
- What does EPS (diluted) mean?
- The profit earned per share, assuming all potential sources of new shares are converted into stock.
- How do you interpret EPS (diluted)?
- An increase indicates strong earnings growth even when accounting for potential share dilution, signaling robust financial performance.
- How does EPS (diluted) compare across companies?
- Standard metric for public companies; peers with complex capital structures are evaluated primarily on diluted EPS.